564 related articles for article (PubMed ID: 17400764)
1. Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness.
Gaspar NJ; Li L; Kapoun AM; Medicherla S; Reddy M; Li G; O'Young G; Quon D; Henson M; Damm DL; Muiru GT; Murphy A; Higgins LS; Chakravarty S; Wong DH
Mol Pharmacol; 2007 Jul; 72(1):152-61. PubMed ID: 17400764
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment.
Medicherla S; Li L; Ma JY; Kapoun AM; Gaspar NJ; Liu YW; Mangadu R; O'Young G; Protter AA; Schreiner GF; Wong DH; Higgins LS
Anticancer Res; 2007; 27(6B):4149-57. PubMed ID: 18229422
[TBL] [Abstract][Full Text] [Related]
3. Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function.
Schniewind B; Groth S; Sebens Müerköster S; Sipos B; Schäfer H; Kalthoff H; Fändrich F; Ungefroren H
Oncogene; 2007 Jul; 26(33):4850-62. PubMed ID: 17297450
[TBL] [Abstract][Full Text] [Related]
4. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
[TBL] [Abstract][Full Text] [Related]
5. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
[TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor beta responses in skin fibroblasts.
Mori Y; Ishida W; Bhattacharyya S; Li Y; Platanias LC; Varga J
Arthritis Rheum; 2004 Dec; 50(12):4008-21. PubMed ID: 15593186
[TBL] [Abstract][Full Text] [Related]
7. Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells.
Zhong Z; Carroll KD; Policarpio D; Osborn C; Gregory M; Bassi R; Jimenez X; Prewett M; Liebisch G; Persaud K; Burtrum D; Wang S; Surguladze D; Ng S; Griffith H; Balderes P; Doody J; Schwartz JD; Youssoufian H; Rowinsky EK; Ludwig DL; Witte L; Zhu Z; Wu Y
Clin Cancer Res; 2010 Feb; 16(4):1191-205. PubMed ID: 20145179
[TBL] [Abstract][Full Text] [Related]
8. A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection.
Suzuki E; Kim S; Cheung HK; Corbley MJ; Zhang X; Sun L; Shan F; Singh J; Lee WC; Albelda SM; Ling LE
Cancer Res; 2007 Mar; 67(5):2351-9. PubMed ID: 17332368
[TBL] [Abstract][Full Text] [Related]
9. Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation.
Rowland-Goldsmith MA; Maruyama H; Kusama T; Ralli S; Korc M
Clin Cancer Res; 2001 Sep; 7(9):2931-40. PubMed ID: 11555612
[TBL] [Abstract][Full Text] [Related]
10. Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells.
Duda DG; Sunamura M; Lefter LP; Furukawa T; Yokoyama T; Yatsuoka T; Abe T; Inoue H; Motoi F; Egawa S; Matsuno S; Horii A
Oncogene; 2003 Oct; 22(44):6857-64. PubMed ID: 14534532
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibitors of type I receptor kinase block cellular transforming growth factor-beta signaling.
Ge R; Rajeev V; Subramanian G; Reiss KA; Liu D; Higgins L; Joly A; Dugar S; Chakravarty J; Henson M; McEnroe G; Schreiner G; Reiss M
Biochem Pharmacol; 2004 Jul; 68(1):41-50. PubMed ID: 15183116
[TBL] [Abstract][Full Text] [Related]
12. Silencing of transforming growth factor-beta1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo.
Moore LD; Isayeva T; Siegal GP; Ponnazhagan S
Clin Cancer Res; 2008 Aug; 14(15):4961-70. PubMed ID: 18676771
[TBL] [Abstract][Full Text] [Related]
13. The tumor suppressor KLF11 mediates a novel mechanism in transforming growth factor beta-induced growth inhibition that is inactivated in pancreatic cancer.
Buck A; Buchholz M; Wagner M; Adler G; Gress T; Ellenrieder V
Mol Cancer Res; 2006 Nov; 4(11):861-72. PubMed ID: 17114344
[TBL] [Abstract][Full Text] [Related]
14. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
Zhang F; Lee J; Lu S; Pettaway CA; Dong Z
Clin Cancer Res; 2005 Jun; 11(12):4512-20. PubMed ID: 15958637
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of breast cancer metastases by a novel inhibitor of TGFβ receptor 1.
Fang Y; Chen Y; Yu L; Zheng C; Qi Y; Li Z; Yang Z; Zhang Y; Shi T; Luo J; Liu M
J Natl Cancer Inst; 2013 Jan; 105(1):47-58. PubMed ID: 23178439
[TBL] [Abstract][Full Text] [Related]
16. Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer.
Ischenko I; Guba M; Yezhelyev M; Papyan A; Schmid G; Green T; Fennell M; Jauch KW; Bruns CJ
Angiogenesis; 2007; 10(3):167-82. PubMed ID: 17486419
[TBL] [Abstract][Full Text] [Related]
17. A novel transforming growth factor beta receptor kinase inhibitor, A-77, prevents the peritoneal dissemination of scirrhous gastric carcinoma.
Kawajiri H; Yashiro M; Shinto O; Nakamura K; Tendo M; Takemura S; Node M; Hamashima Y; Kajimoto T; Sawada T; Ohira M; Hirakawa K
Clin Cancer Res; 2008 May; 14(9):2850-60. PubMed ID: 18451253
[TBL] [Abstract][Full Text] [Related]
18. Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line.
Ehata S; Hanyu A; Fujime M; Katsuno Y; Fukunaga E; Goto K; Ishikawa Y; Nomura K; Yokoo H; Shimizu T; Ogata E; Miyazono K; Shimizu K; Imamura T
Cancer Sci; 2007 Jan; 98(1):127-33. PubMed ID: 17129361
[TBL] [Abstract][Full Text] [Related]
19. TGFbeta inhibition of yolk-sac-like differentiation of human embryonic stem-cell-derived embryoid bodies illustrates differences between early mouse and human development.
Poon E; Clermont F; Firpo MT; Akhurst RJ
J Cell Sci; 2006 Feb; 119(Pt 4):759-68. PubMed ID: 16449320
[TBL] [Abstract][Full Text] [Related]
20. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.
Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE
Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
